Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance

Advanced prostate cancer frequently escapes androgen receptor pathway inhibition through mechanisms including restored androgen signaling, lineage plasticity, and metabolic adaptation. Neuroendocrine prostate cancer (NEPC) can emerge as an androgen-insensitive lineage and has mostly been studied in the context of its transcriptional and epigenetic reprogramming. However, evidence increasingly supports the requirement for metabolic rewiring across a variety of pathways in the transition to NEPC. In this issue of the JCI , Wei et al. demonstrated that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) stabilizes the plastic state of NEPC by supporting serotonin-based posttranslational modification (serotonylation) of mTOR and FOXM1/E2F1 activation. These findings position TPH1 as both a neuroendocrine marker and a functional mediator of hormone therapy resistance. Because metabolic escape can involve many pathways, biomarker-guided patient selection will be required for translating these findings to an intervention. Accordingly, targeting TPH1 may delay or reverse therapy-induced NEPC in selected patients.

Authors

Publication Details

Journal
Journal of Clinical Investigation
Published
2026-11-15
DOI
https://doi.org/10.1172/jci210677
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance

Kevin Holm, Neil A. Bhowmick
Journal of Clinical Investigation
Prostate Cancer Treatment and Research
article

Serotonin biosynthesis emerges as a metabolic driver in prostate cancer therapy resistance

Kevin Holm, Neil A. Bhowmick
article en

Abstract

Advanced prostate cancer frequently escapes androgen receptor pathway inhibition through mechanisms including restored androgen signaling, lineage plasticity, and metabolic adaptation. Neuroendocrine prostate cancer (NEPC) can emerge as an androgen-insensitive lineage and has mostly been studied in the context of its transcriptional and epigenetic reprogramming. However, evidence increasingly supports the requirement for metabolic rewiring across a variety of pathways in the transition to NEPC. In this issue of the JCI , Wei et al. demonstrated that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) stabilizes the plastic state of NEPC by supporting serotonin-based posttranslational modification (serotonylation) of mTOR and FOXM1/E2F1 activation. These findings position TPH1 as both a neuroendocrine marker and a functional mediator of hormone therapy resistance. Because metabolic escape can involve many pathways, biomarker-guided patient selection will be required for translating these findings to an intervention. Accordingly, targeting TPH1 may delay or reverse therapy-induced NEPC in selected patients.

Journal of Clinical InvestigationVol. 136(22)
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon